Abstract
Industrial zones are prevalent in central Taiwan, with major sources of ambient air pollution including large thermal power plants and steel manufacturing facilities. Fine particulate matter (PM₂.₅) is a critical component of air pollution and has been implicated in the development and progression of chronic respiratory diseases (CRDs), primarily through pathways involving immune dysregulation and persistent low-grade inflammation. Oligo-fucoidan (OF), a low–molecular-weight derivative of fucoidan, has been reported to exert immunomodulatory and anti-inflammatory effects in experimental and preclinical studies. However, clinical evidence regarding its potential role in air pollution–associated respiratory conditions remains limited. This exploratory, non-randomized, open-label study aimed to descriptively evaluate changes in immune and inflammatory parameters among patients with air pollution–associated chronic pulmonary diseases residing in central Taiwan. A total of 46 participants received OF supplementation (2.2 g daily) for 12 weeks in addition to standard care. Blood samples were collected at baseline and at weeks 4, 8, and 12 to assess biochemical indices, lymphocyte subsets, inflammatory cytokines, and serum heavy metal concentrations. Ambient PM₂.₅ data during the study period were obtained from nearby governmental air quality monitoring stations. Ambient PM₂.₅ concentrations during the study period were within a relatively low range (11.1 ± 4.0 to 14.7 ± 10.3 µg/m³). Over the 12-week supplementation period, descriptive variations were observed in several immune and inflammatory markers, including white blood cell count, C-reactive protein, ferritin levels, lymphocyte subset distributions, and selected cytokines. Serum mercury concentrations demonstrated a positive association with ambient PM₂.₅ levels. Among the measured cytokines, IL-8 values at later time points were lower than at baseline; these changes are presented descriptively and should be interpreted cautiously given the exploratory, single-arm nature of the study. This exploratory study provides a descriptive characterization of immune, inflammatory, and heavy metal–related parameters in patients with air pollution–associated chronic pulmonary diseases receiving oligo-fucoidan as an adjunct to standard therapy. While causal relationships and statistically confirmed longitudinal effects cannot be established, these preliminary observations may inform the design of future controlled trials and mechanistic investigations in the context of environmental respiratory health.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
References
Collaborators, G. B. D. C. R. D. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine 59, 101936 (2023).
Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396 (10258), 1204–1222 (2020).
Hahn, O. et al. Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies. Biomedicines. 8 (12), 585 (2020).
Zhao, J. et al. Role of PM(2.5) in the development and progression of COPD and its mechanisms. Respir Res. 20 (1), 120 (2019).
Wang, Q. & Liu, S. The Effects and Pathogenesis of PM2.5 and Its Components on Chronic Obstructive Pulmonary Disease. Int. J. Chron. Obstruct Pulmon Dis. 18, 493–506 (2023).
Yan, M. et al. Long-term PM(2.5) exposure in association with chronic respiratory diseases morbidity: A cohort study in Northern China. Ecotoxicol. Environ. Saf. 244, 114025 (2022).
Hao, Y. et al. Quantification of primary and secondary sources to PM(2.5) using an improved source regional apportionment method in an industrial city, China. Sci. Total Environ. 706, 135715 (2020).
Kuang, B. et al. Chemical characterization, formation mechanisms and source apportionment of PM(2.5) in north Zhejiang Province: The importance of secondary formation and vehicle emission. Sci. Total Environ. 851 (Pt 2), 158206 (2022).
Chen, C. R., Lai, H. C., Liao, M. I., Hsiao, M. C. & Ma, H. W. Health risk assessment of trace elements of ambient PM(2.5) under monsoon patterns. Chemosphere 264 (Pt 1), 128462 (2021).
Xing, Y. F., Xu, Y. H., Shi, M. H. & Lian, Y. X. The impact of PM2.5 on the human respiratory system. J. Thorac. Dis. 8 (1), E69–74 (2016).
Nemmar, A. et al. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. Am. J. Respir Crit. Care Med. 164 (9), 1665–1668 (2001).
Laing, S. et al. Airborne particulate matter selectively activates endoplasmic reticulum stress response in the lung and liver tissues. Am. J. Physiol. Cell. Physiol. 299 (4), C736–C749 (2010).
Zhai, X., Wang, J., Sun, J. & Xin, L. PM(2.5) induces inflammatory responses via oxidative stress-mediated mitophagy in human bronchial epithelial cells. Toxicol. Res. (Camb). 11 (1), 195–205 (2022).
Wang, M. et al. Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence. Br. J. Cancer. 132 (11), 986–996 (2025).
Tsai, Y. G. et al. Long-term PM(2.5) exposure impairs lung growth and increases airway inflammation in Taiwanese school children. ERJ Open. Res. 11 (4), 00972–2024 (2025).
Chen, C. H. et al. The effects of fine and coarse particulate matter on lung function among the elderly. Sci. Rep. 9 (1), 14790 (2019).
Wang, J. et al. Urban particulate matter triggers lung inflammation via the ROS-MAPK-NF-kappaB signaling pathway. J. Thorac. Dis. 9 (11), 4398–4412 (2017).
Pang, L. et al. Fine particulate matter induces airway inflammation by disturbing the balance between Th1/Th2 and regulation of GATA3 and Runx3 expression in BALB/c mice. Mol. Med. Rep. 23 (5), 378 (2021).
Liu, K., Hua, S. & Song, L. PM2.5 Exposure and Asthma Development: The Key Role of Oxidative Stress. Oxid. Med. Cell. Longev. 2022, 3618806 (2022).
Ahmad, T. et al. Anti-Inflammatory Activity of Fucoidan Extracts In Vitro. Mar. Drugs. 19 (12), 702 (2021).
Obluchinskaya, E. D., Pozharitskaya, O. N. & Shikov, A. N. In Vitro Anti-Inflammatory Activities of Fucoidans from Five Species of Brown Seaweeds. Mar. Drugs. 20 (10), 606 (2022).
Cumashi, A. et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 17 (5), 541–552 (2007).
Cao, L. M. et al. Antitumor activity of fucoidan: a systematic review and meta-analysis. Transl Cancer Res. 10 (12), 5390–5405 (2021).
Herath, K. et al. The Role of Fucoidans Isolated from the Sporophylls of Undaria pinnatifida against Particulate-Matter-Induced Allergic Airway Inflammation: Evidence of the Attenuation of Oxidative Stress and Inflammatory Responses. Molecules. 25 (12), 2869 (2020).
Liyanage, N. M. et al. Fucoidan from Sargassum autumnale Inhibits Potential Inflammatory Responses via NF-kappaB and MAPK Pathway Suppression in Lipopolysaccharide-Induced RAW 264.7 Macrophages. Mar. Drugs. 21 (7), 374 (2023).
Ye, J. et al. Fucoidan Isolated from Saccharina japonica Inhibits LPS-Induced Inflammation in Macrophages via Blocking NF-kappaB, MAPK and JAK-STAT Pathways. Mar. Drugs. 18 (6), 328 (2020).
Apostolova, E. et al. Immunomodulatory and Anti-Inflammatory Effects of Fucoidan: A Review. Polym. (Basel). 12 (10), 2338 (2020).
Xu, Z. et al. Absorption Patterns of Fucoidan Oligosaccharides from Kjellmaniella crassifolia in the Caco-2 Monolayer Cell Model and Their Pharmacokinetics in Mice. Foods. 14 (9), 1486 (2025).
Sun, X. et al. Orally administrated fucoidan and its low-molecular-weight derivatives are absorbed differentially to alleviate coagulation and thrombosis. Int. J. Biol. Macromol. 255, 128092 (2024).
Hwang, P. A., Phan, N. N., Lu, W. J., Ngoc Hieu, B. T. & Lin, Y. C. Low-molecular-weight fucoidan and high-stability fucoxanthin from brown seaweed exert prebiotics and anti-inflammatory activities in Caco-2 cells. Food Nutr. Res. 60, 32033 (2016).
Liu, T. C., Shih, C. J. & Chiou, Y. L. Oral administration of oligo fucoidan improves the survival rate, quality of life, and immunity in patients with lung cancer. Food Nutr. Res. 68, 10674 (2024).
Chiang, Y. F., Huang, K. C., Huang, P. S., Ali, M. & Hsia, S. M. Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial. Biomedicines. 13 (8), 1970 (2025).
Nie, M. et al. Protective effects of fucoidan against hyperoxic lung injury via the ERK signaling pathway. Mol. Med. Rep. 17 (1), 1813–1818 (2018).
Gao, W. et al. Ameliorative and protective effects of fucoidan and sodium alginate against lead-induced oxidative stress in Sprague Dawley rats. Int. J. Biol. Macromol. 158, 662–669 (2020).
Xue, M. et al. Protective effect of fucoidan against iron overload and ferroptosis-induced liver injury in rats exposed to alcohol. Biomed. Pharmacother. 153, 113402 (2022).
Davis, T. A., Volesky, B. & Mucci, A. A review of the biochemistry of heavy metal biosorption by brown algae. Water Res. 37 (18), 4311–4330 (2003).
Silbajoris, R. et al. Ambient particulate matter induces interleukin-8 expression through an alternative NF-kappaB (nuclear factor-kappa B) mechanism in human airway epithelial cells. Environ. Health Perspect. 119 (10), 1379–1383 (2011).
Wang, J. et al. PM(2.5) stimulated the release of cytokines from BEAS-2B cells through activation of IKK/NF-kappaB pathway. Hum. Exp. Toxicol. 38 (3), 311–320 (2019).
Zhu, J. et al. Effects of Different Components of PM(2.5) on the Expression Levels of NF-kappaB Family Gene mRNA and Inflammatory Molecules in Human Macrophage. Int. J. Environ. Res. Public. Health. 16 (8), 1408 (2019).
Acknowledgements
This study was supported by the equipment of Hungkuang University, Kuang-Tien General Hospital, and Cheng Ching Hospital Chung Kang Branch. Financial support was availed from Hi-Q Marine Biotech International Ltd, Hungkuang University, Kuang-Tien General Hospital, and Cheng Ching Hospital Chung Kang Branch.The authors had full access to all the data from the study and take full responsibility for the integrity of the data and accuracy of the data analysis.
Funding
This research was funded by Hi-Q Marine Biotech International Ltd., Hungkuang University and Cheng Ching Hospital Chung Kang Branch, grant number HK110-091 and.HK-CCGH-112-01.
Author information
Authors and Affiliations
Contributions
Author Contributions: methodology, Chia-Ju Shih; validation, Ya-ling Chiou.; formal analysis, Chia-Ju Shih, Ya-ling Chiou; investigation, Chia-Ju Shih, Ya-ling Chiou; resources, Tu-Chen Liu.; data curation, Juei-Nan Cho, Chia-Ju Shih and Ya-ling Chiou; writing-original draft preparation, Ya-ling Chiou; writing-review and editing, Ya-ling Chiou.; visualization, Ya-ling Chiou.; supervision, Tu-Chen Liu.; project administration, Juei-Nan Cho and Chia-Ju Shih.; funding acquisition, Ya-ling Chiou. All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest related to the publication of this manuscript.
Informed consent statement
Informed consent was obtained from all subjects involved in the study.
Institutional review board statement
T The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Cheng Ching Hospital (HP2110034) and was prospectively registered in the Thai Clinical Trials Registry (TCTR; registration number: TCTR20260126009).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Cho, JN., Shih, CJ., Liu, TC. et al. Immune, inflammatory, and metal biomarker profiles in chronic respiratory diseases receiving oligo-fucoidan under ambient PM₂.₅ exposure. Sci Rep (2026). https://doi.org/10.1038/s41598-026-42873-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-42873-6
